https://immatics.com/: Immatics Presents Data Update on Dose

https://immatics.com/: Immatics Presents Data Update on Dose Escalation from Ongoing ACTengine Cell Therapy Programs


https://immatics.com/: Immatics Presents Data Update on Dose Escalation from Ongoing ACTengine Cell Therapy Programs
·
cancer
·
Tumor shrinkage observed in 8 out of 10 patients including one partial response consistent with robust biological activity of infused T cell products
·
Houston, Texas
and Tuebingen, Germany, March 17, 2021 -
Immatics N.V.(NASDAQ: IMTX, "Immatics"), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, today announced a clinical data update from the dose escalation cohorts of the company's ongoing Phase 1 trials for its engineered Adoptive Cell Therapy approach (also known as TCR-T). The treatment of patients with ACTengine product candidates IMA201, IMA202 and IMA203 at initial dose levels below one billion transduced cells, intended to establish safety and first biological activity, showed first anti-tumor activity with 9 out of 10 evaluable patients showing disease control as well as tumor shrinkage observed in 8 out of 10 patients including one partial response. Clinical observations were consistent with observed robust engraftment, persistence and tumor infiltration of infused ACTengine T cells. Overall, all product candidates demonstrated a manageable safety and tolerability profile. Each of the ACTengine product candidates harness the patient's own T cells, which are genetically engineered to express a novel, proprietary T cell receptor (TCR) directed against a defined cancer target.

Related Keywords

Germany , Houston , Texas , United States , John Graziano , Harpreet Singh , Cedrik Britten , Anja Heuer , Immatic Actengine , Linkedin , Corporate Communications , Trophic Communications , Adoptive Cell Therapy , Chief Executive Officer , Chief Medical Officer , Adoptive Cell Therapies , Looking Statements , Https , Immatics , Presents , Data , Update , Dose , Escalation , From , Ongoing , Actengine , Cell , Therapy , Programs , ஜெர்மனி , ஹூஸ்டன் , டெக்சாஸ் , ஒன்றுபட்டது மாநிலங்களில் , ஜான் கிரஜியனோ , ஹார்பிரீத் சிங் , அஞ்ச ஹ்ய்யூவர் , சென்டர் , பெருநிறுவன தகவல்தொடர்புகள் , தலைமை நிர்வாகி அதிகாரி , தலைமை மருத்துவ அதிகாரி , பார்க்கிறது அறிக்கைகள் , த்தப்ஸ் , ப்ரெஸெஂட்ஸ் , தகவல்கள் , புதுப்பிப்பு , டோஸ் , இருந்து , செல் , சிகிச்சை , ப்ரோக்ர்யாம்ஸ் ,

© 2025 Vimarsana